Paul Buchanan
Dr
Dr Buchanan obtained his PhD in 2010 from Queen’s University
Belfast, where his research involved investigating the cell and molecular
biology aspects involved in pathogen host interaction in cystic fibrosis
epithelia. Following this he took up the position as a Postdoctoral fellow at
the Royal College of Surgeons in Ireland based within the National Children’s
Research Centre. Here his work focused on the role of ion channels in altered
epithelial proliferation and migration as well as inflammatory responses in
cystic fibrosis. This generated his interest in the area of channelopathies and
their underlying molecular mechanisms. He was then appointed as a Postdoctoral fellow
at the Centre for Cancer Research and Cell biology within Queen’s University
Belfast. During this period Dr Buchanan continued is interest in
channelopthaies investigating the role of calcium channels in driving castrate
resistant prostate cancer.
In 2016 Dr Buchanan was appointed lecturer and principle investigator at Dublin City University within the School of Nursing and Human Science. Here he is continuing his research of ion channels in cancer from within the National Institute of Cellular Biotechnology. His teaching roles include module co-ordinator and lecturer for the modules Understanding the body, Biological basis of disease and Clinical Pharmacology for Nursing.
Furthermore he is a member of the management committee for Ireland on the EU COST Action - Ion Channels and Immune Response toward a global understanding of immune cell physiology and for new therapeutic approaches (IONCHAN-IMMUNRESPON) (BM1406).
In 2016 Dr Buchanan was appointed lecturer and principle investigator at Dublin City University within the School of Nursing and Human Science. Here he is continuing his research of ion channels in cancer from within the National Institute of Cellular Biotechnology. His teaching roles include module co-ordinator and lecturer for the modules Understanding the body, Biological basis of disease and Clinical Pharmacology for Nursing.
Furthermore he is a member of the management committee for Ireland on the EU COST Action - Ion Channels and Immune Response toward a global understanding of immune cell physiology and for new therapeutic approaches (IONCHAN-IMMUNRESPON) (BM1406).
Peer Reviewed Journal
| Year | Publication | |
|---|---|---|
| 2022 | Debbie O'Reilly, Tim Downing, Sana Kouba, Marie Potier-Cartereau, Declan J McKenna, Christophe Vandier, Paul J Buchanan (2022) 'Data pertaining to aberrant intracellular calcium handling during androgen deprivation therapy in prostate cancer'. Data In Brief, . [DOI] | |
| 2021 | DebbieO'Reilly, Tim Downing, Sana Kouba, Marie Potier-Cartereau, Declan J. McKenna, Christophe Vandier, Paul J. Buchanan (2021) 'CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer'. Cell Calcium, . [Link] https://doi.org/10.1016/j.ceca.2022.102554 | |
| 2021 | Redmond J;McCarthy H;Buchanan P;Levingstone TJ;Dunne NJ; (2021) 'Advances in biofabrication techniques for collagen-based 3D in vitro culture models for breast cancer research'. Materials Science and Engineering C, 122 . [DOI] | |
| 2021 | Bracken-Clarke D;Kapoor D;Baird AM;Buchanan PJ;Gately K;Cuffe S;Finn SP; (2021) 'Vaping and lung cancer - A review of current data and recommendations'. Lung Cancer (Amsterdam, Netherlands), 153 . [DOI] | |
| 2020 | Barrett, M;Dhuibhir, PU;Njoroge, C;Wickham, S;Buchanan, P;Aktas, A;Walsh, D (2020) 'Diet and nutrition information on nine national cancer organisation websites: A critical review'. European Journal of Cancer Care, . [DOI] | |
| 2019 | O'Reilly D.;Johnson P.;Buchanan P. (2019) 'Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer'. Steroids, 152 . [DOI] | |
| 2019 | O'Reilly D.;Buchanan P. (2019) 'Calcium channels and cancer stem cells'. Cell Calcium, 81 :21-28. [DOI] | |
| 2018 | McDonnell BM;Buchanan PJ;Prise KM;McCloskey KD; (2018) 'Acute radiation impacts contractility of guinea-pig bladder strips affecting mucosal-detrusor interactions'. PLoS ONE, 13 (3). [DOI] | |
| 2018 | Loughran, ST;Power, PA;Maguire, PT;McQuaid, SL;Buchanan, PJ;Jonsdottir, I;Newman, RW;Harvey, R;Johnson, PA (2018) 'Influenza infection directly alters innate IL-23 and IL-12p70 and subsequent IL-17A and IFN-gamma responses to pneumococcus in vitro in human monocytes'. PLoS ONE, 13 . [DOI] | |
| 2017 | Redmond, J;O'Rilley, D;Buchanan, P (2017) 'Role of Ion Channels in Natural Killer Cell Function Towards Cancer'. Discovery medicine, 23 :353-360. | |
| 2016 | Buchanan, PJ;McCloskey, KD (2016) 'Ca-V channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeutics'. European Biophysics Journal, 45 :621-633. [DOI] | |
| 2017 | Haggag YA, Matchett KB, Dakir El-H, Buchanan P, Osman MA, Elgizawy SA, El-Tanani M, Faheem AM, McCarron PA (2017) 'Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells'. International Journal of Pharmaceutics, 521 (1-2):40-53. [DOI] | |
| 2015 | Higgins G;Ringholz F;Buchanan P;McNally P;Urbach V; (2015) 'Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential'. BioMed Research International, 2015 . [DOI] | |
| 2014 | Ringholz FC;Buchanan PJ;Clarke DT;Millar RG;McDermott M;Linnane B;Harvey BJ;McNally P;Urbach V; (2014) 'Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis'. European Respiratory Journal, 44 (2). [DOI] | |
| 2014 | Higgins G;Buchanan P;Perriere M;Al-Alawi M;Costello RW;Verriere V;McNally P;Harvey BJ;Urbach V; (2014) 'Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis'. American Journal of Respiratory Cell and Molecular Biology, 51 (2). [DOI] | |
| 2014 | Al-Alawi M;Buchanan P;Verriere V;Higgins G;McCabe O;Costello RW;McNally P;Urbach V;Harvey BJ; (2014) 'Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium'. Physiological Reports, 2 (8). [DOI] | |
| 2013 | Urbach V;Higgins G;Buchanan P;Ringholz F; (2013) 'The role of Lipoxin A4 in Cystic Fibrosis Lung Disease'. Computational and Structural Biotechnology Journal, 6 . [DOI] | |
| 2013 | Kelly C;Canning P;Buchanan PJ;Williams MT;Brown V;Gruenert DC;Elborn JS;Ennis M;Schock BC; (2013) 'Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells'. American Journal of Physiology - Lung Cellular and Molecular Physiology, 304 (5). [DOI] | |
| 2013 | Buchanan PJ;McNally P;Harvey BJ;Urbach V; (2013) 'Lipoxin A₄-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair'. American Journal of Physiology - Lung Cellular and Molecular Physiology, 305 (2). [DOI] | |
| 2011 | Scott A;Weldon S;Buchanan PJ;Schock B;Ernst RK;McAuley DF;Tunney MM;Irwin CR;Elborn JS;Taggart CC; (2011) 'Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo'. PLoS ONE, 6 (10). [DOI] | |
| 2009 | Buchanan PJ;Ernst RK;Elborn JS;Schock B; (2009) 'Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation'. Biochemical Society Transactions, 37 (Pt 4). [DOI] |
Conference Publication
Certain data included herein are derived from the © Web of Science (2022) of Clarivate. All rights reserved.
Honors and Awards
Research Interests
Prostate Cancer
Cancer
Channelopathies
Cell and Molecular Physiology
Cancer
Channelopathies
Cell and Molecular Physiology